Press Releases

Date Title and Summary Additional Formats  
Toggle Summary Karyopharm to Present at the 35th Annual J.P. Morgan Healthcare Conference
NEWTON, Mass. , Jan. 03, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman , MD, PhD, Chief Executive Officer, will present at the 35 th Annual J.P. Morgan Healthcare Conference in San Francisco on
View HTML
Toggle Summary Karyopharm to Participate in Upcoming Investor Conferences
NEWTON, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the management team will participate in the following upcoming investor conferences: Canaccord Genuity Rare Disease and BioPharma 1x1
View HTML
Toggle Summary Karyopharm Announces the Presentation of New Data at the 2017 American Association for Cancer Research Annual Meeting
Late-Breaking Presentation Highlighting Interim Phase 2b Selinexor Data in Patients with Relapsed or Refractory DLBCL (SADAL Study) Presentations Include Eleven Preclinical Abstracts Describing Key Scientific Findings across the Company's Oncology Programs Overview of Key Selinexor Myeloma Data
View HTML
Toggle Summary Karyopharm Announces Results from Interim Analysis of Phase 2 SOPRA Study Evaluating Selinexor in Relapsed/Refractory Acute Myeloid Leukemia
Study Will Not Reach Statistically Significant Improvement in Primary Endpoint of Overall Survival in Patients who are Unfit for Chemotherapy and/or Transplantation ; Patients Deriving Benefit to Remain on Study Clinical Development Continuing in Promising Induction and Combination Settings NEWTON,
View HTML
Toggle Summary Karyopharm to Report Fourth Quarter and Year End 2016 Financial Results on March 16, 2017
Conference Call Scheduled for Thursday, March 16, 2017 at 8:30 a.m. ET
View HTML
Toggle Summary Karyopharm Announces Partial Clinical Hold to Pause Enrollment in Selinexor Trials
All Currently Enrolled Patients with Stable Disease or Better Can Continue Receiving Selinexor Company Has Amended Investigator's Brochure and Informed Consent Documents as Requested by FDA Company Expects Timelines for Both Ongoing and Planned Studies to Remain Materially Unchanged NEWTON, Mass.,
View HTML
Toggle Summary Karyopharm Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Selinexor Clinical Update
− Overall Response Rate of 28.4% Observed in Phase 2b SADAL Study in Relapsed/Refractory DLBCL; Additional Top-line Data to be Presented as a Late-Breaker at AACR 2017 Annual Meeting — − Company Announces FDA-Affirmed Development Path for Selinexor in DLBCL with Potential for Accelerated Approval —
View HTML
Toggle Summary Karyopharm to Present at the 16th Annual Needham Healthcare Conference
NEWTON, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 16th Annual Needham Healthcare Conference in New York on Wednesday,
View HTML
Toggle Summary U.S. FDA Division of Hematology Products Lifts Partial Clinical Hold on Karyopharm's Selinexor Clinical Trials
Recruitment Resumes Across All Selinexor Trials in Hematological Malignancies Timelines for Ongoing and Planned Studies Expected to Remain Materially Unchanged NEWTON, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company,
View HTML
Toggle Summary Karyopharm to Present Selinexor Phase 2b SADAL Data at the American Association for Cancer Research Annual Meeting 2017
Abstract Published Today Highlighting Interim Phase 2b SADAL Results in Patients with Relapsed or Refractory DLBCL Overall Response Rate Greater Than 28%, along with Additional Updated Data, to Be Presented in a Late-Breaking Poster at the Meeting NEWTON, Mass., March 31, 2017 (GLOBE NEWSWIRE) --
View HTML